Alembic Builds US Launch Pipeline As It Looks To Oncology Arena
Alembic is building up an extensive roster of solid-dose, ophthalmic and dermatological drugs to introduce in the US. With facility clearance from the FDA, the Indian firm can now target the US market for oral solids to treat cancer.
You may also be interested in...
With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.
The continuing sartans crisis and new product launches in US helped Alembic to post a strong Q2 performance, despite slowdown in other markets.
Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.